{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:41:50Z","timestamp":1779230510116,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T00:00:00Z","timestamp":1607731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T00:00:00Z","timestamp":1607731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Transcatheter tricuspid valve repair (TTVR) is a promising technique for the treatment of tricuspid regurgitation (TR). Data comparing the performance of novel edge-to-edge devices (PASCAL and MitraClip-XTR) are scarce.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We identified 80 consecutive patients who underwent TTVR using either the PASCAL or MitraClip-XTR system to treat symptomatic TR from July 2018 to June 2020. To adjust for baseline imbalances, we performed a propensity score (PS) 1:1 matching. The primary endpoint was a reduction in TR severity by at least one grade at 30\u00a0days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The PS-matched cohort (<jats:italic>n<\/jats:italic>\u2009=\u200944) was at high-surgical risk (EuroSCORE II: 7.5% [interquartile range (IQR) 4.8\u201312.1%]) with a mean TR grade of 4.3\u2009\u00b1\u20090.8 and median coaptation gap of 6.2\u00a0mm [IQR 3.2\u20139.1\u00a0mm]. The primary endpoint was similarly observed in both groups (PASCAL: 91% vs. MitraClip-XTR: 96%). Multiple device implantation was the most common form (59% vs. 82%, <jats:italic>p<\/jats:italic>\u2009=\u20090.19), and the occurrence of SLDA was comparable between the PASCAL and MitraClip-XTR system (5.7% [2 of 35 implanted devices] vs. 4.4% [2 of 45 implanted devices], <jats:italic>p<\/jats:italic>\u2009=\u20090.99). No periprocedural death or conversions to surgery occurred, and 30-day mortality (5.0% vs. 5.0%, log-rank <jats:italic>p<\/jats:italic>\u2009=\u20090.99) and 3-month mortality (10.0% vs. 5.0%, log-rank <jats:italic>p<\/jats:italic>\u2009=\u20090.56) were similar between both groups. During follow-up, functional NYHA class, 6-min walking distance, and health status improved in both groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Both TTVR devices, PASCAL and MitraClip-XTR, appeared feasible and comparable for an effective TR reduction. Randomized head-to-head comparisons will help to further define the appropriate scope of application of each system.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00392-020-01784-w","type":"journal-article","created":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T16:02:22Z","timestamp":1607788942000},"page":"451-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["PASCAL versus MitraClip-XTR edge-to-edge device for the treatment of tricuspid regurgitation: a propensity-matched analysis"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9446-9963","authenticated-orcid":false,"given":"Atsushi","family":"Sugiura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Vogelhuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zita","family":"Schwaibold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Reckers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadahiro","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Refik","family":"Kavsur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc Ulrich","family":"Becher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Nickenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,12]]},"reference":[{"issue":"12","key":"1784_CR1","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jcmg.2014.07.018","volume":"7","author":"Y Topilsky","year":"2014","unstructured":"Topilsky Y, Nkomo VT, Vatury O, Michelena HI, Letourneau T, Suri RM, Pislaru S, Park S, Mahoney DW, Biner S et al (2014) Clinical outcome of isolated tricuspid regurgitation. JACC Cardiovasc imaging 7(12):1185\u20131194","journal-title":"JACC Cardiovasc imaging"},{"issue":"3","key":"1784_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jcmg.2018.11.021","volume":"12","author":"PE Bartko","year":"2019","unstructured":"Bartko PE, Arfsten H, Frey MK, Heitzinger G, Pavo N, Cho A, Neuhold S, Tan TC, Strunk G, Hengstenberg C et al (2019) natural history of functional tricuspid regurgitation: implications of quantitative doppler assessment. JACC Cardiovasc imaging 12(3):389\u2013397","journal-title":"JACC Cardiovasc imaging"},{"issue":"19","key":"1784_CR3","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1161\/CIRCULATIONAHA.116.024848","volume":"135","author":"G Nickenig","year":"2017","unstructured":"Nickenig G, Kowalski M, Hausleiter J, Braun D, Schofer J, Yzeiraj E, Rudolph V, Friedrichs K, Maisano F, Taramasso M et al (2017) Transcatheter treatment of severe tricuspid regurgitation with the edge-to-edge MitraClip technique. Circulation 135(19):1802\u20131814","journal-title":"Circulation"},{"issue":"15","key":"1784_CR4","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.jcin.2019.04.038","volume":"12","author":"L Asmarats","year":"2019","unstructured":"Asmarats L, Perlman G, Praz F, Hensey M, Chrissoheris MP, Philippon F, Ofek H, Ye J, Puri R, Pibarot P et al (2019) Long-Term outcomes of the FORMA transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation: insights from the first-in-human experience. JACC Cardiovasc Interv 12(15):1438\u20131447","journal-title":"JACC Cardiovasc Interv"},{"issue":"24","key":"1784_CR5","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1016\/j.jcin.2019.09.046","volume":"12","author":"NP Fam","year":"2019","unstructured":"Fam NP, Braun D, von Bardeleben RS, Nabauer M, Ruf T, Connelly KA, Ho E, Thiele H, Lurz P, Weber M et al (2019) Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: a multicenter, observational. First-in-Human Experience JACC Cardiovasc Interv 12(24):2488\u20132495","journal-title":"First-in-Human Experience JACC Cardiovasc Interv"},{"issue":"15","key":"1784_CR6","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.jacc.2019.01.062","volume":"73","author":"G Nickenig","year":"2019","unstructured":"Nickenig G, Weber M, Schueler R, Hausleiter J, N\u00e4bauer M, von Bardeleben RS, Sotiriou E, Sch\u00e4fer U, Deuschl F, Kuck KH et al (2019) 6-Month outcomes of tricuspid valve reconstruction for patients with severe tricuspid regurgitation. J Am Coll Cardiol 73(15):1905\u20131915","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1784_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcin.2018.10.022","volume":"12","author":"M Taramasso","year":"2019","unstructured":"Taramasso M, Alessandrini H, Latib A, Asami M, Attinger-Toller A, Biasco L, Braun D, Brochet E, Connelly KA, Denti P et al (2019) Outcomes after current transcatheter tricuspid valve intervention: mid-term results from the International TriValve Registry. JACC Cardiovasc Interv 12(2):155\u2013165","journal-title":"JACC Cardiovasc Interv"},{"issue":"12","key":"1784_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jcin.2018.05.002","volume":"11","author":"C Besler","year":"2018","unstructured":"Besler C, Orban M, Rommel KP, Braun D, Patel M, Hagl C, Borger M, Nabauer M, Massberg S, Thiele H et al (2018) Predictors of procedural and clinical outcomes in patients with symptomatic tricuspid regurgitation undergoing transcatheter edge-to-edge repair. JACC Cardiovasc Interv 11(12):1119\u20131128","journal-title":"JACC Cardiovasc Interv"},{"issue":"10213","key":"1784_CR9","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/S0140-6736(19)32600-5","volume":"394","author":"G Nickenig","year":"2019","unstructured":"Nickenig G, Weber M, Lurz P, von Bardeleben RS, Sitges M, Sorajja P, Hausleiter J, Denti P, Trochu JN, N\u00e4bauer M et al (2019) Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet (London, England) 394(10213):2002\u20132011","journal-title":"Lancet (London, England)"},{"issue":"6","key":"1784_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jcin.2018.11.028","volume":"12","author":"D Braun","year":"2019","unstructured":"Braun D, Rommel KP, Orban M, Karam N, Brinkmann I, Besler C, Massberg S, Nabauer M, Lurz P, Hausleiter J (2019) Acute and short-term results of transcatheter edge-to-edge repair for severe tricuspid regurgitation using the MitraClip-XTR system. JACC Cardiovasc Interv 12(6):604\u2013605","journal-title":"JACC Cardiovasc Interv"},{"issue":"8","key":"1784_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11886-020-01305-1","volume":"22","author":"N Corpataux","year":"2020","unstructured":"Corpataux N, Winkel MG, Kassar M, Brugger N, Windecker S, Praz F (2020) The PASCAL device-early experience with a leaflet approximation device: what are the benefits\/limitations compared with the MitraClip? Current cardiology reports 22(8):74","journal-title":"Current cardiology reports"},{"issue":"12","key":"1784_CR12","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1093\/ehjci\/jex139","volume":"18","author":"RT Hahn","year":"2017","unstructured":"Hahn RT, Zamorano JL (2017) The need for a new tricuspid regurgitation grading scheme. Eur Heart J Cardiovasc Imaging 18(12):1342\u20131343","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"1784_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ejcts\/ezx324","volume":"52","author":"V Falk","year":"2017","unstructured":"Falk V, Baumgartner H, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Munoz DR et al (2017) 2017 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg 52(4):616\u2013664","journal-title":"Eur J Cardiothorac Surg"},{"issue":"2","key":"1784_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jacc.2017.03.011","volume":"70","author":"RA Nishimura","year":"2017","unstructured":"Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O\u2019Gara PT et al (2017) 2017 AHA\/ACC Focused Update of the 2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 70(2):252\u2013289","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"1784_CR15","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.jacc.2019.02.010","volume":"73","author":"SV Arnold","year":"2019","unstructured":"Arnold SV, Chinnakondepalli KM, Spertus JA, Magnuson EA, Baron SJ, Kar S, Lim DS, Mishell JM, Abraham WT, Lindenfeld JA et al (2019) Health Status After Transcatheter Mitral-Valve Repair in Heart Failure and Secondary Mitral Regurgitation: COAPT Trial. J Am Coll Cardiol 73(17):2123\u20132132","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1784_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1513\/AnnalsATS.201706-485OC","volume":"15","author":"T Goto","year":"2018","unstructured":"Goto T, Hirayama A, Faridi MK, Camargo CA Jr, Hasegawa K (2018) Obesity and severity of acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc 15(2):184\u2013191","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"1784_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jchf.2019.12.006","volume":"8","author":"M Orban","year":"2020","unstructured":"Orban M, Rommel KP, Ho EC, Unterhuber M, Pozzoli A, Connelly KA, Deseive S, Besler C, Ong G, Braun D et al (2020) Transcatheter edge-to-edge tricuspid repair for severe tricuspid regurgitation reduces hospitalizations for heart failure. JACC Heart Fail 8(4):265\u2013276","journal-title":"JACC Heart Fail"},{"issue":"9","key":"1784_CR18","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/ehjci\/jez032","volume":"20","author":"M Andreas","year":"2019","unstructured":"Andreas M, Russo M, Taramasso M, Zuber M, Mascherbauer J (2019) Novel transcatheter clip device (MitraClip-XTR) enables significant tricuspid annular size reduction. Eur Heart J Cardiovasc Imaging 20(9):1070","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"1784_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/ehjci\/jey153","volume":"20","author":"A Sugiura","year":"2019","unstructured":"Sugiura A, Weber M, Sinning JM, Werner N, Nickenig G (2019) Staged transcatheter valve repair via MitraClip-XTR after Cardioband for tricuspid regurgitation. Eur Heart J Cardiovasc Imaging 20(1):118","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"9","key":"1784_CR20","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1093\/ehjci\/jez024","volume":"20","author":"C Santoro","year":"2019","unstructured":"Santoro C, Marco Del Castillo A, Gonz\u00e1lez-G\u00f3mez A, Monteagudo JM, Hinojar R, Lorente A, Abell\u00e1s M, Vieitez JM, Garcia Mart\u00ecn A, Casas Rojo E et al (2019) Mid-term outcome of severe tricuspid regurgitation: are there any differences according to mechanism and severity? Eur Heart J Cardiovasc Imaging 20(9):1035\u20131042","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1784_CR21","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.cjca.2020.07.001","volume":"36","author":"A Fisicaro","year":"2020","unstructured":"Fisicaro A, Sticchi A, Mangieri A, Laricchia A, Squeri A, Colombo A (2020) Giannini F (2020) Acute tricuspid valve remodeling after MitraClip deployment: rationale for a dual-staged procedure. Can J Cardiol 36:1831-e1","journal-title":"Can J Cardiol"},{"issue":"10","key":"1784_CR22","first-page":"E298","volume":"31","author":"A Sugiura","year":"2019","unstructured":"Sugiura A, Weber M, Sinning JM, Werner N, Nickenig G (2019) Provisional closure of an iatrogenic atrial septal defect for shunt reversal after transcatheter treatment of tricuspid regurgitation. J Invasive Cardiol 31(10):E298-e299","journal-title":"J Invasive Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01784-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-020-01784-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01784-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T13:07:28Z","timestamp":1616504848000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-020-01784-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,12]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1784"],"URL":"https:\/\/doi.org\/10.1007\/s00392-020-01784-w","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,12]]},"assertion":[{"value":"5 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AS, JV, C\u00d6, ZS, DR, TG, RK, MUB, and SZ have no conflicts of interest. MW has received lecture or proctoring fees from Abbott, Boehringer-Ingelheim, Edwards Lifesciences, Neochord, Pfizer, and Servier. GN has received research funding from the Deutsche Forschungsgemeinschaft, the German Federal Ministry of Education and Research, the EU, Abbott, AGA Medical, AstraZeneca, Bayer, Berlin Chemie, Biosensus, Biotronic, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Edwards Lifesciences, Medtronic, Novartis, Pfizer, Sanofi, and St Jude Medical, and has received honoraria for lectures or advisory boards from Abbott, AGA Medical, AstraZeneca, Bayer, Berlin, Cardiovalve, Berlin Chemie, Biosensus, Biotronic, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Edwards Lifesciences, Medtronic, Novartis, Pfizer, Sanofi, and St Jude Medical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}